CME/CE
Jointly provided by Partners for Advancing Clinical Education (Partners) and DKBmed, LLC.
Acknowledgement
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Target Audience
The intended audience for this Clinician Webcast will be clinicians treating patients with CRSwNP, primarily otolaryngologists, but also allergists and pulmonologists, nurses, nurse practitioners, and physician assistants.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Discuss the pathophysiology and burden of CRSwNP.
- Identify challenges present in conventional treatment options for CRSwNP.
- Discuss the clinical trial data for monoclonal antibodies that treat CRSwNP and the role that otolaryngologists can play in appropriately using these medications.
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty / Presenter Reported Financial Relationship Faculty Conflicts of Interest
| Faculty | Conflicts of Interest |
| Stella Lee, MD | Consultant/Advisor/Speaker with AstraZeneca, Genentech Novartis, GSK, Lyra Therapeutics, Optinose, Sanofi Regeneron, Diceros Therapeutics |
| Kathleen Buchheit, MD | Consultant/Advisor/Speaker with AstraZeneca, GSK, Sanofi, Regeneron, Eli Lilly
Royalties or Patent Beneficiary at UpToDate |
| Michael Wechsler, MD | Consultant/Advisor/Speaker with Abbvie, Allakos, Apogee, Areteia Therapeutics, Arrowhead Pharmaceutical, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Enveda therapeutics, Equillium, General Medicines, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, recludix Pharma, Roche/Genentech, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Uniquity Bio, Verona Pharma, Zurabio, AstraZeneca, Amgen, Regeneron, Glaxosmithkline, Sanofi/Genzyme, Upstream Bio Stock Options from Cellergy Pharma Inc and Upstream Bio |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and DKBmed LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until August 31, 2026. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating and receiving CME/CE credit for this activity.
Request for Credit
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
- Release date: September 1, 2025
- Expiration date: August 31, 2026
Estimated time to complete the activity: 60 minutes
Hardware & Software Requirements
To access activities, users will need:
- A computer with an internet connection
- An HTML5 compliant web browser or Internet Explorer 8 (and higher)
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com